World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
27030
World Ranking
17902
National Ranking
8931

Ugo De Giorgi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ugo De Giorgi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 606 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ugo De Giorgi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ugo De Giorgi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ugo De Giorgi is affiliated with the University of Salento in Italy. Their research primarily spans the field of Medicine, with particular focus on several subfields, including Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research, and Radiology, Nuclear Medicine and Imaging.

De Giorgi's research topics cover various aspects of cancer treatment and diagnostics, highlighting areas such as Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Renal Cell Carcinoma Treatment, Cancer Genomics and Diagnostics, Bladder and Urothelial Cancer Treatments, Radiopharmaceutical Chemistry and Applications, and PARP Inhibition in Cancer Therapy.

Their recent publications include the following papers:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, 2020, The Lancet
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial, 2023, The Lancet
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, 2020, New England Journal of Medicine

De Giorgi has frequently published in several scientific journals, among which the most prolific venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Frontiers in Oncology
  • Cancers

The scientist has collaborated extensively with a number of frequent co-authors, with notable collaboration counts including:

  • Giuseppe Procopio (92 co-authored works)
  • Chiara Casadei (84 co-authored works)
  • Sebastiano Buti (79 co-authored works)
  • Giuseppe Fornarini (75 co-authored works)
  • Vincenza Conteduca (69 co-authored works)

Best Publications

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

    Matthew D. Galsky;José Ángel Arranz Arija;Aristotelis Bamias;Ian D. Davis

  • Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

    Bernard Escudier;Camillo Porta;Petri Bono;Thomas Powles

  • Plasma AR and abiraterone-resistant prostate cancer.

    Alessandro Romanel;Delila Gasi Tandefelt;Vincenza Conteduca;Anuradha Jayaram;Anuradha Jayaram

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

    Lorch A;Beyer J;Bascoul-Mollevi C

  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

    Cora N. Sternberg;Karim Fizazi;Fred Saad;Neal D. Shore

  • Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - Results from an international study group

    Karim Fizazi;Sergei Tjulandin;Roberto Salvioni;José R. Germà-Lluch

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Robert L Coleman;Domenica Lorusso;Christine Gennigens;Antonio González-Martín

  • Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

    Johann S de Bono;Ugo De Giorgi;Daniel Nava Rodrigues;Christophe Massard

  • Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

    Mario Giuliano;Mario Giuliano;Mario Giuliano;Antonio Giordano;Antonio Giordano;Summer Jackson;Kenneth R Hess

  • Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

    Anja Lorch;Caroline Bascoul-Mollevi;Andrew Kramar;Lawrence Einhorn

  • Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Matthew Smith;Johann De Bono;Cora Sternberg;Sylvestre Le Moulec

  • Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

    Sumanta K. Pal;Jonathan E. Rosenberg;Jean H. Hoffman-Censits;Raanan Berger

  • Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

    Ugo De Giorgi;Giuseppe Procopio;Diana Giannarelli;Roberto Sabbatini

  • Germ-cell tumors.

    Ugo De Giorgi;Paolo Pedrazzoli;Giovanni Rosti

Frequent Co-Authors

Daniele Santini
Daniele Santini Università Campus Bio-Medico
Cora N. Sternberg
Cora N. Sternberg Cornell University
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Sandro Pignata
Sandro Pignata National Cancer Institute
Thomas Powles
Thomas Powles Queen Mary University of London
Dino Amadori
Dino Amadori University of Bologna
Giovanni Paganelli
Giovanni Paganelli Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Gerhardt Attard
Gerhardt Attard University College London
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The journey to a medical career in the USA is evolving, with a growing number of online degrees offering flexibility and a wide range of options. For students interested in healthcare fields beyond the MD, several accredited programs can help you advance your career.

An important consideration is accreditation. Prospective healthcare administrators should explore which online healthcare degree programs are recognized for their accreditation by cahme? Choosing such programs ensures your education is respected by employers and meets industry standards.

Nurses seeking to upgrade their qualifications often ask: does rn to bsn require clinicals? Many online programs now offer flexible pathways that minimize or waive clinical components for experienced RNs, making advancement more accessible.

Advanced nursing degrees are also available online, with options to fast-track your credentials. Discover the shortest msn to dnp program for those looking to move quickly into leadership or advanced practice roles.

Flexibility is key, and some professionals may prefer online dnp programs without clinicals to balance work and studies.

Whether pursuing administration, nursing, or advanced medical education, these pathways offer varied and accessible routes to a rewarding healthcare career in the USA.

Best Scientists Citing Ugo De Giorgi

Trending Scientists

Recently Published Articles